In the era of immunotherapy, large randomized clinical trials have reported promising outcomes for anti-PD-1/PD-L1 directed therapies in patients with various cancers, such as lung cancer, melanoma and renal cell carcinoma [27,28]. The gene discussed is CD274; the disease is lung carcinoma.